Antibody-drug conjugates — ADCs — are among the hottest things in oncology, and the headline is always the antibody: the smart guided missile that finds the cancer. But that framing misses where the difficulty, and the demand, actually sit.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
The science: an ADC is three parts, two of them chemistry
An ADC has three components. The antibody finds the target. A linker holds a toxin to the antibody and releases it only inside the tumor. And a payload — a cytotoxic warhead far too poisonous to give on its own — does the killing. The breakout drug Enhertu pairs a HER2 antibody with a topoisomerase-inhibitor payload via a precisely-engineered cleavable linker, and its "bystander effect" — the released toxin drifting into neighboring cells — is a property of the payload-and-linker chemistry, not the antibody. [1]
It is worth pausing on that division of labor. The antibody is the address — a biologic, grown in living cells. But the two components that turn a targeting protein into a drug that actually kills cancer are small-molecule chemistry. The whole appeal of the format is that it lets you use a toxin so potent it could never be dosed on its own; the antibody restricts where that poison is unleashed. The therapeutic idea is biological, but the thing that has to be synthesized, to exacting standards, is the linker and the payload.
How the machine works inside the tumor
Follow one ADC molecule through its job. It circulates until its antibody arm binds a protein on the surface of a tumor cell. The cell internalizes the whole complex, drawing it into an acidic, enzyme-rich compartment. There the linker is meant to give way — cleaved by the local chemistry — and free the payload, which attacks the machinery the cell needs to divide. The cell dies. That is the ideal path: bind, internalize, cleave, kill.
Two design ideas make the format more than the sum of its parts. The first is the bystander effect. If the freed payload can slip across cell membranes, it doesn't only kill the cell that swallowed it — it drifts into neighbors, including tumor cells that carry little or none of the target protein. For solid tumors, where the target is expressed unevenly, that reach matters a great deal, and it is dialed in through the payload and how the linker releases it.
The second is the drug-to-antibody ratio — how many payload molecules ride on each antibody. Load too few and the drug is under-powered; load too many and the conjugate can become unstable, clear too fast, or turn insoluble. The sweet spot is a balance struck in chemistry and process, not biology — one more reason the interesting engineering in an ADC lives on the small-molecule side.
Payloads and linkers: the two pieces of chemistry
Payloads cluster into a few workhorse classes. Microtubule inhibitors jam the internal scaffolding a cell uses to pull itself apart when it divides; they were the mainstay of the earlier generation of ADCs. Topoisomerase inhibitors — the class behind the current wave of successful conjugates — jam the enzyme that relaxes tangled DNA and trap it on the strand, turning routine DNA maintenance into lethal breaks, and they have proved well-suited to the bystander-effect designs driving today's momentum. Other classes go after DNA directly or block other essential processes. What every one of them shares is extreme potency: these are molecules engineered to kill at vanishingly small doses, which is exactly what makes them valuable on an antibody and dangerous everywhere else.
Linkers split into two broad philosophies. Cleavable linkers are built to break under conditions found inside the target cell — an acidic compartment, specific enzymes, or the different chemical environment inside a cell versus the bloodstream — releasing a payload that is then free to travel and produce the bystander effect. Non-cleavable linkers hold on until the antibody itself is broken down, releasing the payload still attached to a fragment of the linker; these tend to be more stable in circulation but keep the toxin more tightly confined to the cell that took it up. Neither is simply better. The choice is a set of trade-offs among potency, stability, safety, and how far you want the payload to reach.
The upshot is that "an ADC" is a chemistry recipe as much as a biologic. Swap the payload class, change the linker strategy, retune the ratio, and you get a materially different drug against the very same antibody target — and all of it runs on the specialized chemistry side of the molecule.
Why high-potency chemistry is a narrow, capital-intensive lane
Here is the commercial pinch point. The payloads are, by design, some of the most toxic compounds handled anywhere in pharmaceutical manufacturing. You cannot make them in an ordinary plant alongside ordinary drugs. They demand dedicated high-containment facilities — sealed isolators, specialized air handling, rigorous worker-protection and cleaning regimes — engineered so that the people making the compound are never exposed to it. Building that kind of suite is expensive, slow to qualify, and hard to repurpose. It is a genuinely narrow lane, and only a handful of suppliers have committed the capital to operate in it at scale.
The conjugation step — chemically attaching payloads to antibodies through the linker — is its own specialized bottleneck. It marries two very different manufacturing worlds: the biologic antibody, made in living systems, and the high-potency small molecule, made by synthetic chemistry. Doing that join reproducibly, at commercial volume, under containment, with tight control over how many payloads land on each antibody, is a capability few contract manufacturers have built out — and every new program competes for slots in the same finite set of high-containment suites and conjugation lines.
That is why capacity, not chemistry cleverness, is often the binding constraint. What an antibody franchise cannot conjure on demand is a qualified high-potency payload supply and a booked conjugation line. When demand for a scarce, capital-intensive capability rises faster than new capacity can be validated, the leverage sits with whoever controls the capacity.
The demand: a small-molecule business inside a biologics headline
This is why the ADC boom is quietly a small-molecule demand story. Cytotoxic payloads and cleavable linkers are specialized, high-potency chemistry — made in dedicated, contained facilities by a small number of capable suppliers, because the compounds are too toxic to handle in an ordinary plant. As every antibody franchise races to build an ADC version, the demand isn't really for more antibodies; it's for payloads, linkers, and the conjugation capacity to join them.
In the radar, the ADC targets — HER2 and newer ones like TROP2 — keep climbing. But the antibody side of that is biology. The part that has to be synthesized, to exacting standards, is the linker and the payload — where a narrow supplier base meets a widening field of developers. It is exactly the kind of lane the radar is built to surface, because it looks at the chemistry rather than the modality label on the box. A story that presents as a biologics headline is, underneath, a demand pull on a specialized corner of small-molecule manufacturing.
Who sits in the value chain
Several distinct groups feel this pull, each from a different angle. High-potency API and payload makers are the warhead suppliers — the chemists who can synthesize and handle these toxins safely at scale. They sit closest to the scarce resource and are the most direct beneficiaries of rising ADC demand. Conjugation CDMOs — the contract manufacturers who own the high-containment suites and the antibody-to-payload joining lines — are the other choke point; their booked capacity is, in practice, the throttle on how fast the field can grow.
Then there are the antibody makers, who supply the targeting arm and increasingly want an ADC version of every franchise they own, and the oncology developers designing and running the clinical programs, deciding which target, payload class, and linker strategy to bet on. These players sit on the demand side, competing for the same finite payload supply and conjugation slots. The useful question is where in this chain value concentrates as programs multiply: it tends to pool wherever capacity is hardest to add, which today is the high-potency and conjugation lanes rather than the antibody itself.
The caveats: safety, CMC, and the antibody still matters
None of this should be read as "the antibody doesn't matter." It matters enormously — a poorly chosen targeting arm can sink a program no matter how elegant the payload, and target selection, clean binding, and reliable internalization are all first-order problems. The argument here is narrower: the hard-to-source and capacity-constrained parts of an ADC are the payload, linker, and conjugation — and that is where a demand read pays off.
The safety picture is a genuine caveat too. Because the payloads are so potent, off-target release, premature linker cleavage in circulation, or uptake by healthy tissue can all produce serious toxicity, and much of the clinical difficulty in the field is about managing exactly those failure modes. The chemistry and manufacturing side — what the industry calls CMC — is correspondingly unforgiving: controlling the drug-to-antibody ratio, keeping the conjugate stable, and proving batch-to-batch consistency under containment are all points where programs stumble.
So the observation is directional, not deterministic. Many programs will fail on safety or on manufacturability rather than on demand. But the structural fact underneath the noise is durable: a widening set of developers is chasing a narrow, capital-intensive supply of high-potency chemistry and conjugation capacity. That imbalance is the signal worth watching, and it is a chemistry signal wearing a biologics headline.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.